Table 2.

Laboratory findings in patients with P. vivax malaria on admission and follow-up

Parameter	Primaquine 30 mg	Primaquine 60 mg	Both groups
Platelets (×109/L) D0	111 ± 82; N = 41	112 ± 73; N = 41	111 ± 77; N = 82
Platelets (×109/L) D7	288 ± 77; N = 38	274 ± 105; N = 37	281 ± 92; N = 75
Platelets (×109/L) D14	281 ± 100; N = 34	285 ± 104; N = 37	283 ± 101; N = 71
Platelets (×109/L) D28	232 ± 64; N = 27	227 ± 56; N = 32	229 ± 59; N = 59
Serum creatinine (mg/dL) D0	1.0 ± 0.2; N = 42	1.0 ± 0.3; N = 42	1.0 ± 0.2; N = 84
Serum creatinine (mg/dL) D7	0.9 ± 0.1; N = 39	0.9 ± 0.1; N = 38	0.9 ± 0.1; N = 77
Serum creatinine (mg/dL) D14	0.9 ± 0.1; N = 34	1.0 ± 0.1; N = 37	0.9 ± 0.1; N = 71
Serum creatinine (mg/dL) D28	0.9 ± 0.2; N = 27	0.9 ± 0.1; N = 32	0.9 ± 0.1; N = 59
Total bilirubin (mg/dL) D0	1.1 (0.4–5.4); N = 42	1.0 (0.1–4.1); N = 42	1.1 (0.1–5.4); N = 84
Total bilirubin (mg/dL) D7	0.6 (0.3–1.6); N = 39	0.6 (0.3–1.3); N = 38	0.6 (0.3–1.6); N = 77
Total bilirubin (mg/dL) D14	0.5 (0.2–1.4); N = 34	0.5 (0.3–1.2); N = 37	0.5 (0.2–1.4); N = 71
Total bilirubin (mg/dL) D28	0.5 (0.3–1.0); N = 27	0.4 (0.3–1.7); N = 32	0.5 (0.3–1.7); N = 59
SGPT (U/L) D0	24 (8–84); N = 42	19 (5–147); N = 42	21 (5–147); N = 84
SGPT (U/L) D7	32 (11–146); N = 39	24 (5–65); N = 38	27 (5–146); N = 77
SGPT (U/L) D14	35 (11–199); N = 34	20 (10–105); N = 37	26 (10–199); N = 71
SGPT (U/L) D28	22 (10–78); N = 27	18 (7–87); N = 32	19 (7–87); N = 59

D = Days after initiation of primaquine treatment; D0 = pretreatment values.